Does Amiodarone (Amio) treat atrial fibrillation (afib)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, amiodarone (Amio) is used to treat atrial fibrillation (afib). It's an antiarrhythmic medication that works by stabilizing the electrical activity of the heart, helping to restore and maintain normal rhythm. According to the most recent guidelines 1, amiodarone is considered a suitable alternative agent for heart rate control when conventional measures are ineffective.

Key Points to Consider

  • Amiodarone is typically started at a loading dose of 400-600 mg daily for 2-4 weeks, then reduced to a maintenance dose of 100-200 mg daily 1.
  • It can be administered orally or intravenously in emergency situations.
  • While effective for controlling afib, amiodarone requires careful monitoring due to potential side effects involving the thyroid, lungs, liver, and eyes 1.
  • Regular follow-up appointments with blood tests to check thyroid and liver function are necessary.
  • Patients should be aware that amiodarone has a very long half-life, meaning it stays in the body for weeks to months after stopping treatment.

Important Considerations for Treatment

  • Amiodarone may cause potentially fatal toxicity, including pulmonary fibrosis, hepatic injury, and proarrhythmia 1.
  • High-dose oral amiodarone loading can worsen hemodynamics in patients with recent decompensation of HF or hypotension.
  • The potential benefit of amiodarone must be carefully weighed against the considerable potential toxicity of this drug.

Recommendations for Use

  • Amiodarone should be used with caution and under close monitoring, particularly in patients with structural heart disease where other antiarrhythmics might be contraindicated 1.
  • It is often reserved as a second-line treatment when other medications have failed or aren't tolerated.

From the Research

Amiodarone Treatment for Atrial Fibrillation

  • Amiodarone is a commonly prescribed medication for treating and preventing atrial fibrillation (AF) 2, 3, 4, 5, 6.
  • The European Society of Cardiology AF guidelines recommend amiodarone for long-term rhythm control in all AF patients, but suggest considering other antiarrhythmic drugs first due to its extracardiac toxicity 2.
  • Studies have shown that amiodarone is effective in maintaining sinus rhythm in patients with AF, particularly those with congestive heart failure (CHF) 3, 5.
  • Amiodarone has been used to block atrioventricular conduction, decrease ventricular rate during AF, and as prophylaxis against paroxysmal AF and recurrence of AF after DC conversion to sinus rhythm 4.
  • A meta-analysis found that amiodarone was more effective than a placebo or rate control drug in achieving sinus rhythm, but was associated with a higher risk of adverse effects 5.
  • Combination therapy with amiodarone and flecainide may be effective in controlling refractory atrial flutter and fibrillation in patients with structural cardiac disease 6.

Efficacy and Safety of Amiodarone

  • Amiodarone has been shown to be effective in restoring sinus rhythm in paroxysmal and persistent AF patients with CHF 3.
  • The drug has been associated with a significant decrease in B-type natriuretic peptide (BNP) levels and an increase in left ventricular ejection fraction (LVEF) in patients with CHF 3.
  • However, amiodarone has a high toxicity profile, and its use has been associated with non-cardiovascular mortality and severe side effects 2, 5.
  • The risk of adverse effects, such as skin discoloration and hypogonadism, may be mitigated by combination therapy with other antiarrhythmic drugs or dose reduction 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Is amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation?

Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2022

Research

Amiodarone in atrial fibrillation.

Acta medica Scandinavica, 1984

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.